Takeda Pharmaceutical (NYSE:TAK) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Takeda Pharmaceutical from a "buy" to a "strong-buy" rating in a note to investors.
• Takeda missed Q4 estimates, reporting $0.48 EPS versus a $0.55 consensus and $7.60B revenue versus $7.81B, and set FY2025 guidance at about 3.16 EPS.
• The stock carries a consensus rating of "Moderate Buy," with a market cap of ~$57.6B, a PE of 75.4, and a 12‑month range of $12.99 to $18.90.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a note issued to investors on Saturday.

Several other analysts also recently weighed in on TAK. Zacks Research raised shares of Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 3rd. Weiss Ratings reissued a "hold (c-)" rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley assumed coverage on shares of Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an "overweight" rating for the company. Finally, Sanford C. Bernstein raised shares of Takeda Pharmaceutical from a "market perform" rating to an "outperform" rating in a research note on Wednesday. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy".

Takeda Pharmaceutical Stock Performance

Takeda Pharmaceutical stock opened at $18.10 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $57.59 billion, a PE ratio of 75.40 and a beta of -0.01. The firm has a fifty day simple moving average of $18.22 and a two-hundred day simple moving average of $15.99. Takeda Pharmaceutical has a twelve month low of $12.99 and a twelve month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.07). The business had revenue of $7.60 billion during the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. Research analysts expect that Takeda Pharmaceutical will post 1.64 EPS for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Private Trust Co. NA raised its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company's stock valued at $27,000 after acquiring an additional 783 shares during the last quarter. True Wealth Design LLC raised its stake in shares of Takeda Pharmaceutical by 1,262.3% during the third quarter. True Wealth Design LLC now owns 2,711 shares of the company's stock valued at $40,000 after acquiring an additional 2,512 shares during the last quarter. Parkside Financial Bank & Trust raised its stake in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company's stock valued at $40,000 after acquiring an additional 1,684 shares during the last quarter. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at about $42,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company's stock valued at $48,000 after acquiring an additional 2,328 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited NYSE: TAK is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda's main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.